Cognetivity Neurosciences Ltd. announced the publication of the latest scientific paper on its Integrated Cognitive Assessment (ICA) in the peer-reviewed academic journal Frontiers in Psychiatry. The new paper provides further evidence of the validity of the ICA as a digital cognitive biomarker for detecting and monitoring patients with mild cognitive impairment (MCI) and mild Alzheimer's Disease. It also reaffirms the ICA's sensitivity in detecting cognitive impairment at the early stages of Alzheimer's Disease, when treatment is known to be at its most effective. Key amongst the paper's findings is that the ICA performs consistently in different international populations and that its results can be generalized across them, without the need to collect population-specific normative data in new environments. Traditional cognitive tests, whether pen-and-paper-based or computerized, require the collection of language and culture-specific data in new global locations before they can be deployed at scale. By contrast, the new data on Cognetivity's ICA, obtained in a multinational cohort of more than 200 study participants, demonstrate that the ICA is unbiased by differences in language, culture and education, and therefore naturally suitable for rapid, population-wide deployment across the globe, including risk-based screening in primary care. Combined with its powerful use of explainable artificial intelligence (AI), the ICA's inherent avoidance of demographic bias also points to its ability to enable granular patient stratification – a significant and growing trend in the pharmaceutical industry. By characterising patients independently of their linguistic, cultural or educational backgrounds, the ICA has the potential to identify not just individuals in need of treatment but those most likely to benefit from a particular type of pharmacological intervention, regardless of where in the world they come from. The paper also reports on the ICA's capacity to measure cognitive performance remotely without loss of testing accuracy, showcasing the platform's capability as a high-frequency monitoring tool both in the clinic and in the safety of patients' homes. Thus, it is well placed to meet the pressing need, accelerated by the COVID-19 pandemic, for high-quality remote cognitive assessment.